Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
Oslo, Norway, 15 July 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces the start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab. All safety reviews during the dose escalation phase have been completed with no Dose Limiting Toxicities (DLT) reported and the five US hospital sites are now open for further recruitment. This phase I/II trial investigates the safety, biologic and anti-tumor activity of ONCOS-102 in